Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Lindsay M GurskaRachel OkabeAlexandra SchurerMeng Maxine TongMark SotoDaniel ChoiKristina AmesShira G Glushakow-SmithAllison MontoyaEllen TeinLinde A MilesHaiying ChengPamela A Hankey-GiblinRoss L LevineSwati GoelBalazs HalmosKira GritsmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In summary, we demonstrate that crizotinib has preclinical efficacy in MPN patient cells, JAK2-mutated cell lines, and a JAK2-mutated mouse model, and that the combination of crizotinib with JAK inhibitors suppresses JAK inhibitor persistence. Our work suggests that crizotinib should be investigated for the treatment of patients with MPN.